Objective. To study measures of the plasma antioxidant profile in patients with paranoid schizophrenia and Alzheimer’s disease (AD). Materials and methods. The study included 33 patients with paranoid schizophrenia and 18 patients with AD. Groups of patients with treatment-resistant schizophrenia and responding positively to treatment were identified. Measures of the antioxidant profile were determined by chemiluminometry and spectrofluorimetry. Results and discussion. Systemic oxidative stress due to lack of plasma low molecular weight antioxidants was not seen in AD though “thiol” protein oxidative stress was detected, providing indirect evidence of insufficiency of the glutathione system. Systemic oxidative stress was also not typical of patients with treatment-resistant paranoid schizophrenia while “thiol” oxidative stress was marked. Patients with paranoid schizophrenia and responding to therapy showed the opposite picture – systemic oxidative stress was more intense and “thiol” oxidative stress was less so. Of the neuroleptics studied, haloperidol, zuclopenthixol, risperidone, and ziprasidone had no antioxidant properties, while pericyazine, clozapine, and especially chlorpromazine had marked antioxidant properties, though they were unlikely have effects on plasma antioxidant potential. These results led to the conclusion that the glutathione component of the antioxidant system is most impaired in treatment-resistant paranoid schizophrenia and AD, while systemic antioxidant stress is minor. Oxidative impairments were less pronounced in successfully treated paranoid schizophrenia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
F. Ruiz-Litago, J. Seco, E. Echevarria, et al., “Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: a 12-months follow-up study,” Psychiatry Res., 200, 218–222 (2012), https://doi.org/10.1016/j.psychres.2012.07.024.
J. K. Yao and M. S. Keshavan, “Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view,” Antioxid. Redox Signal, 15, 2011–2035 (2011), https://doi.org/https://doi.org/10.1089/ars.2010.3603.
P. V. Magalhaes, O. Dean, A. C. Andreazza, et al., “Antioxidant treatments for schizophrenia,” Cochrane Database Syst. Rev., 2, CD008919 (2016), https://doi.org/10.1002/14651858.cd008919.pub2.
T. Xie, Q. Li, X. Luo, et al., “Plasma total antioxidant status and cognitive impairments in first-episode drug-naive patients with schizophrenia,” Cogn. Neurodyn., 13, 357–365 (2019), https://doi.org/10.1007/s11571-019-09530-3.
X. F. Li, Y. L. Zheng, M. H. Xiu, et al., “Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 35, 1064–1067 (2011), https://doi.org/10.1016/j.pnpbp.2011.03.001.
M. Reyazuddin, S. A. Azmi, N. Islam, and A. Rizvi, “Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics,” Indian J. Psychiatry, 56, 344–349 (2014).
X. Y. Zhang, D. C. Chen, M. H. Xiu, et al., “Plasma total antioxidant status and cognitive impairments in schizophrenia,” Schizophr. Res., 139, 66–72 (2012), https://doi.org/10.1016/j.schres.2012.04.009.
C. D. Miljevic, A. Nikolic-Kokic, D. Blagojevic, et al., “Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients,” Psychiatry Res., 269, 746–752 (2018), https://doi.org/10.1016/j.psychres.2018.09.009.
T. K. Das, A. Javadzadeh, A. Dey, et al., “Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 91, 94–102 (2019), https://doi.org/10.1016/j.pnpbp.2018.08.006.
Y. Zhang, V. S. Catts, and C. S. Weickert, “Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia,” Aust. N. Z. J. Psychiatry, 52, 690–698 (2018), https://doi.org/https://doi.org/10.1177/0004867417728805.
D. Matsuzawa and K. Hashimoto, “Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia,” Antioxid. Redox Signal, 15, 2057–2065 (2011), https://doi.org/https://doi.org/10.1089/ars.2010.3453.
J. K. Yao, R. Reddy, and D. P. van Kammen, “Reduced level of plasma antioxidant uric acid in schizophrenia,” Psychiatry Res., 80, 29–39 (1998), https://doi.org/https://doi.org/10.1016/s0165-1781(98)00051-1.
I. Sadowska-Bartosz, S. Galiniak, G. Bartosz, et al., “Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia,” Schizophr. Res., 176, 245–251 (2016), https://doi.org/10.1016/j.schres.2016.07.010.
M. Padurariu, A. Ciobica, I. Dobrin, and C. Stefanescu, “Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics,” Neurosci. Lett., 479, 317–320 (2010), https://doi.org/https://doi.org/10.1016/j.neulet.2010.05.088.
M. Pohanka, “Oxidative stress in Alzheimer disease as a target for therapy,” Bratisl. Lek. Listy, 119, 535–543 (2018), https://doi.org/https://doi.org/10.4149/bll_2018_097.
D. A. Butterfield and J. Kanski, “Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid beta-peptide 1-42,” Peptides, 23, 1299–1309 (2002), https://doi.org/https://doi.org/10.1016/s0196-9781(02)00066-9.
C. Exley, E. House, A. Polwart, and M. M. Esiri, “Brain burdens of aluminum, iron, and copper and their relationships with amyloid-beta pathology in 60 human brains,” J. Alzheimers Dis., 31, 725–730 (2012), https://doi.org/https://doi.org/10.3233/jad-2012-120766.
A. M. Roberts, R. Jagadapillai, R. A. Vaishnav, et al., “Increased pulmonary arteriolar tone associated with lung oxidative stress and nitric oxide in a mouse model of Alzheimer’s disease,” Physiol. Rep., 4, e12953 (2016), https://doi.org/10.14814/phy2.12953.
G. Nesi, S. Sestito, M. Digiacomo, and S. Rapposelli, “Oxidative stress, mitochondrial abnormalities and proteins Deposition: Multitarget Approaches in Alzheimer’s disease,” Curr. Top. Med. Chem., 17, 3062–3079 (2017), https://doi.org/https://doi.org/10.2174/1568026617.666170607114232.
P. K. Mandal, M. Tripathi, and S. Sugunan, “Brain oxidative stress: detection and mapping of anti-oxidant marker ‘Glutathione’ in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy,” Biochem. Biophys. Res. Commun., 417, 43–48 (2012), https://doi.org/https://doi.org/10.1016/j.bbrc.2011.11.047.
M. Allen, F. Zou, H. S. Chai, et al., “Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications,” Mol. Neurodegener., 7, 13 (2012), https://doi.org/10.1186/1750-1326-7-13.
H. H. Palacios, B. B. Yendluri, K. Parvathaneni, et al., “Mitochondrion- specific antioxidants as drug treatments for Alzheimer disease,” CNS Neurol. Disord. Drug Targets, 10, 149–162 (2011), https://doi.org/10.2174/187152711794480474.
C. B. Pocernich and D. A. Butterfield, “Elevation of glutathione as a therapeutic strategy in Alzheimer disease,” Biochim. Biophys. Acta, 1822, 625–630 (2012), https://doi.org/https://doi.org/10.1016/j.bbadis.2011.10.003.
M. Zampagni, D. Wright, R. Cascella, et al., “Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models,” Free Radic. Biol. Med., 52, 1362–1371 (2012), https://doi.org/10.1016/j.freeradbiomed.2012.01.012.
N. C. Andreasen, W. T. Carpenter, Jr., J. M. Kane, et al., “Remission in schizophrenia: proposed criteria and rationale for consensus,” Am. J. Psychiatry, 162, No. 3, 441–449 (2005), https://doi.org/https://doi.org/10.1176/appi.ajp.162.3.441.
A. V. Alekseev, E. V. Proskurnina, and Yu. A. Vladimirov, “Determination of antioxidants by activated chemiluminescence using 2,2’- azo-bis(2-amidinopropane),” Vestn. Mosk. Univ. Ser. 2 Khim., 53, No. 3, 187–193 (2012), https://doi.org/10.3103/s0027131412030029.
H. Liu, H. Wang, S. Shenvi, et al., “Glutathione metabolism during aging and in Alzheimer disease,” Ann. NY Acad. Sci., 1019, 346–349 (2004), https://doi.org/10.1196/annals.1297.059.
G. Spalletta, S. Bernardini, L. Bellincampi, et al., “Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease,” Am. J. Geriatr. Psychiatry, 15, 879–887 (2007), https://doi.org/10.1097/jgp.0b013e3.180547076.
C. Capurso, F. Panza, D. Seripa, et al., “Polymorphisms in glutathione S-transferase omega-1 gene and increased risk of sporadic Alzheimer disease,” Rejuvenation Res., 13, 645–652 (2010), https://doi.org/10.1089/rej.2010.1052.
L. N. Porokhovnik, V. P. Pasekov, N. A. Egolina, et al., “Oxidative stress, rRNA genes, and antioxidant enzymes in the pathogenesis of schizophrenia and autism: modeling and clinical guidelines,” Zh. Obshch. Biol., 74, No. 5, 340–353 (2013), https://doi.org/https://doi.org/10.1134/s2079086414050065].
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 120, No. 6, Iss. 1, pp. 82–87, June, 2020.
Rights and permissions
About this article
Cite this article
Sokolova, S.V., Sozarukova, M.M., Khannanova, A.N. et al. Antioxidant Status in Paranoid Schizophrenia and Alzheimer’s Disease. Neurosci Behav Physi 51, 158–162 (2021). https://doi.org/10.1007/s11055-021-01052-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-021-01052-y